Spots Global Cancer Trial Database for A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g)
Official Title: A Phase II, Open-Label, Multicenter Study of the Efficacy and Safety of Single-Agent PRO95780 in Patients With Advanced Chondrosarcoma
Study ID: NCT00543712
Conditions
Interventions
Study Description
Brief Summary: This is a multicenter, open-label, Phase II trial designed to evaluate the efficacy and safety of PRO95780 when given as a single agent in patients with advanced chondrosarcoma. Up to 90 patients with confirmed chondrosarcoma will be enrolled.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sarcoma Oncology Center, Santa Monica, California, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
MD Anderson Cancer Center, Houston, Texas, United States
Peter MacCallum Cancer Centre, Melbourne, , Australia
Contact Details
Name: Sandra Skettino, M.D.
Affiliation: Genentech, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
